Athersys Strikes Deal With Pfizer to Develop Stem Cell Technology for Treatment of Inflammatory Bowel Disease
Athersys, Inc. (Nasdaq:ATHX) announced today that it has entered into an agreement with Pfizer Inc. (PFE) to develop and commercialize MultiStem(R) for the treatment of Inflammatory Bowel Disease (“IBD”). MultiStem is an investigational stem cell therapy currently in development by Athersys for several other conditions, including acute myocardial infarction, bone marrow transplant support, and ischemic stroke.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.